Cue Biopharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Cue Biopharma, Inc., hereby severally constitute and appoint Daniel R. Passeri and Kerri-Ann Millar our true and lawful attorney, with full power to him or her to sign for us and in our names in the capacities indicated below, any amendments to this Annual Report on Form 10-K, and generally to do all things in our names and on our behalf in such capacities to enable Cue Biopharma, Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all the requirements of the Securities Exchange Commission.
Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signatures | Title | Date |
|---|---|---|
| /s/ Daniel R. Passeri | Chief Executive Officer and Director | March 31, 2025 |
| Daniel R. Passeri | (Principal Executive Officer) | |
| /s/ Kerri-Ann Millar | Chief Financial Officer | March 31, 2025 |
| Kerri-Ann Millar | (Principal Financial and Accounting Officer) | |
| /s/ Peter A. Kiener | Director | March 31, 2025 |
| Peter A. Kiener | ||
| /s/ Frederick Driscoll | Director | March 31, 2025 |
|---|---|---|
| Frederick Driscoll | ||
| /s/ Pamela Garzone | Director | March 31, 2025 |
|---|---|---|
| Pamela Garzone | ||
| /s/ Patrick Verheyen | Director | March 31, 2025 |
| Patrick Verheyen | ||
| /s/ Frank Morich | Director | March 31, 2025 |
| Frank Morich | ||
| /s/ Pasha Sarraf | Director | March 31, 2025 |
| Pasha Sarraf | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.